(Q40201943)

English

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

scientific article published on 21 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma (English)

1 reference

Europe PubMed Central

18 September 2017

Angela Dispenzieri

2

1 reference

Europe PubMed Central

18 September 2017

7

object named as

Litzow MR

1 reference

Europe PubMed Central

18 September 2017

11

object named as

Gertz MA

1 reference

Europe PubMed Central

18 September 2017

3

object named as

Lacy MQ

1 reference

Europe PubMed Central

18 September 2017

Francis K Buadi

5

object named as

Buadi FK

1 reference

Europe PubMed Central

18 September 2017

author name string

Kumar S

1

1 reference

Europe PubMed Central

18 September 2017

Hayman SR

4

1 reference

Europe PubMed Central

18 September 2017

Gastineau DA

6

1 reference

Europe PubMed Central

18 September 2017

Fonseca R

8

1 reference

Europe PubMed Central

18 September 2017

Roy V

9

1 reference

Europe PubMed Central

18 September 2017

Rajkumar SV

10

1 reference

Europe PubMed Central

18 September 2017

publication date

21 June 2007

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

21

1 reference

Europe PubMed Central

18 September 2017

2035-2042

1 reference

Europe PubMed Central

18 September 2017

9

1 reference

Europe PubMed Central

18 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404801

0 references

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Impaired PBPC collection in patients with myeloma after high-dose melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404801

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404801

1 reference

Europe PubMed Central

18 September 2017

Dimensions Publication ID

0 references

release_fvriqrxre5halklb4nxyucutui

1 reference

https://api.fatcat.wiki/v0/release/fvriqrxre5halklb4nxyucutui

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40201943&oldid=1888689886"